

**Audrey's Life Science Meeting Picks for Oct. 29, 2017 through March 2018
Complimentary Service of AudreysNetwork.com**

Bio2Device Group, Tuesday Morning, Oct. 31, 2017

Topic: "Opportunities and Challenges for the Health Ecosystem in Emerging Countries"

Speaker: Bert Wank, Founder & CEO, infiniRel Corporation

Date and Time: Tuesday, Oct. 31, 2017, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no registration or fees required for morning meetings.

Topic Description

Emerging markets will power global growth over the next 20 years, a \$31 Trillion Dollar economy. Health, energy, water, are at its the foundation. An economy that is based on meeting basic needs for pregnant women and an agricultural, cash based survival, must focus on the elimination of food- and water-born illnesses, as well as rapid detection, diagnosis, and cost-efficient treatment on a low cost basis. A first hand and personal look at entrepreneurs in India, their challenges and opportunities, will highlight how an eco-system may be created that leverages the best of the West with essential frugal innovation of the East.

Speaker Bio

Bert Wank is founder and CEO of infiniRel Corporation, a Silicon Valley-based start-up that is developing patent-pending power conversion and energy storage solutions for hybrid microgrids.

In 2016 he joined Adtec Electronics Pvt. Ltd. as an Advisor on Power & Energy. He has been instrumental in redefining its business as a systems developer for rural telemedicine, integrating energy and connectivity. He received the personal blessings from Sri Sri Ravi Shankar, the founder of the Art of Living foundation, successfully soliciting four demonstration projects.

Mr. Wank brings over 24 years of experience in product development, program management, applications engineering, international and strategic marketing for power semiconductor products, signal processing platforms, and recently renewable energy systems. In 2012 he was invited to serve as an external director on the Board of Director of Pancon Corporation. His expertise spans solar, wind, biogas, and energy storage technologies, including flywheels, batteries and capacitors. As a cleantech start-up executive, Mr. Wank also volunteered as Metro Director for the Cleantech Open business accelerator in North Texas from 2013 to 2015, and was voted "Cleantech Hero" in 2013. Prior to founding infiniRel, Mr. Wank has launched 14 battery and power management semiconductor product lines at Dallas Semiconductor (acquired by Maxim), Burr-Brown (acquired by Texas Instruments), and austriamicrosystems, a European high-voltage CMOS foundry. Between 2000 and 2001, Mr. Wank also served as Expert Witness to Silicon Valley IP law firm Blakely Sokolof Taylor & Zafman, in an alleged patent infringement relating to battery management.

He holds a BSEE from Germany and an MBA in International Business from Thunderbird, Glendale, AZ. As a dual citizen of the U.S. and Germany he speaks fluent German and English, and basic Mandarin Chinese.

QB3, Thursday Midday, Oct. 31, 2017

Event: "Introduction to the Science Exchange Marketplace at QB3"

Speakers: Nolan McDonnell is the Director of Business Development at Science Exchange and Dr. Zev Wisotsky is a Senior Scientist / Research & Development Specialist at Science Exchange

Date and Time: Tue, October 31, 2017, 12:00 PM – 1:00 PM PDT

Free

Location: Room 212, Byers Hall, 1700 4th Street, UCSF Mission Bay, San Francisco, CA 94158

Register at https://www.eventbrite.com/e/introduction-to-the-science-exchange-marketplace-at-qb3-tickets-38740595163?mc_cid=570318eeb9&mc_eid=cb4c38a44a#tickets

Event Description

Startups moving toward a lean, virtual research model must negotiate contracts as they outsource, spending time that they otherwise could have devoted to innovation. To eliminate busywork and help our startups become more efficient, QB3 has partnered with Science Exchange, an online marketplace. Science Exchange offers a single access point to more than 2,500 qualified service providers, all with pre-established contracts in place to protect client intellectual property and confidentiality.

Join this introductory session to learn how your company can access Science Exchange through QB3's marketplace, and get concierge service from full-time staff who can ensure that you connect with the right providers.

Meet Your Science Exchange Contacts

Nolan McDonnell is the Director of Business Development at Science Exchange where he works closely with R&D organizations to help increase access to innovation, reduce administrative friction, and enhance spend visibility. Prior to joining Science Exchange, Nolan worked at Deloitte Consulting where he drove technology strategy and implementation to enable organizations to achieve key business objectives, including merger and acquisition; pipeline development; commercialization; IPO. Nolan received his BS in biomedical engineering from California Polytechnic State University and is passionate about enhancing R&D with innovative technologies.

Nolan McDonnell, Director of Business Development
Nolan.Mcdonnell@scienceexchange.com
818.723.1545

Zev Wisotsky

Dr. Zev Wisotsky is a Senior Scientist / Research & Development Specialist at Science Exchange where he works closely with scientists to understand their research goals and expedite their outsourcing projects by connecting them with expert service providers. Prior to joining Science Exchange, Zev worked as a postdoctoral researcher at Stanford studying the role of brain regions involved in fear memory and drug withdrawal through silencing different brain circuits by optogenetics. Zev received his PhD in neuroscience from the University of California, Riverside and works hard to provide researchers access to expert scientific service providers.

Zev Wisotsky, PhD, Senior Scientist / Research & Development Specialist
Zev@scienceexchange.com
925.434.5888

JLABS, Thursday Midday, Nov. 2, 2017

Topic: "Let's Talk Legal Workshop | Venture Financing: What to Expect and Strategies for Success"

Speakers: Stuart Wilks | Assistant General Counsel, Johnson & Johnson, Steven A. Wilcox | Partner, Ropes & Gray, Brad Flint | Associate, Ropes & Gray

Date and Time: Thursday, November 2, 2017 from 10:30 AM to 1:00 PM (PDT)

Agenda:

10:30 AM - 11:00 AM | Registration & Networking

11:00 AM - 11:45 AM | Presentation

11:45 AM - 12:00 PM | Q&A

12:00 PM - 1:00 PM | Lunch and Networking

1:00 PM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd. Floor 3, South San Francisco, CA 94080

Ticket Information

Fees:

\$25 | General Public

\$10 | Student/Academic

\$35 | At the door

** Please note: fees do not go to the presenting lawyers, they cover only a portion of catering and event costs

Details and registration at <https://www.eventbrite.com/e/lets-talk-legal-workshop-venture-financing-what-to-expect-and-strategies-for-success-tickets-35582902419?aff=weekly>

Join us for "Let's Talk Legal I Venture Financing: What to Expect and Strategies for Success" –a workshop designed to help entrepreneurs demystify the legal landscape and fill in the blanks. The program is interactive and informal so bring your questions with you!

Program Overview

You're past the initial stages in establishing your startup company and are ready to take it to the next level - raising capital. What should you expect during a pivotal early stage company financing round and what are the strategies for ensuring you meet your objectives and protect your interests?

This practical session will focus on how to approach a venture financing round - key topics include:

Venture capital financing deal structures

Key deal terms that are commonly subject to heavy negotiation

Considerations for protecting founder interests

Strategic investors v. venture capital investors

This event is brought to you by Johnson & Johnson's law department working in close partnership with Ropes & Gray LLP, a preeminent global law firm with deep expertise in life sciences. The lawyers presenting these workshops have extensive experience working with life sciences companies ranging from very early-stage startup companies to global public companies..

Speakers' Bios

Stuart Wilks is Assistant General Counsel at Johnson & Johnson resident at the Johnson & Johnson Innovation Center in Menlo, Park California. In this role, Stuart provides general legal advice to the Innovation Center team in California, participates directly as legal counsel in Innovation Center transactions, and/or coordinates with colleagues in the Johnson & Johnson Law Department to support Innovation Center matters.

During his nearly fifteen years with Johnson & Johnson, in addition to the California Innovation Center, Stuart has supported a diverse group of Johnson & Johnson operating companies and units, such as Alza, BabyCenter, Janssen Health Innovation, Janssen Research & Development, Janssen Supply Chain, Johnson & Johnson Innovation – JJDC, Inc., Noramco, and Scios in a broad range of business and contractual matters. Prior to joining Johnson & Johnson, Stuart was corporate counsel at Scios, Inc. in Fremont, California, corporate counsel at COR Therapeutics, Inc. in South San Francisco, California and an associate in the corporate and life sciences practice groups of the Palo Alto office of Cooley LLP.

Steve Wilcox focuses his practice on mergers and acquisitions, corporate financing transactions (including public offerings and venture capital investments) and licensing and collaborations. Most of his clients are engaged in the biotech, medical device and pharmaceutical industries. In addition to transactional work, he regularly counsels companies on a range of federal securities and corporate governance matters.

Steve is a founder and former chair of the firm's life sciences practice group.

Steve has been counsel to some of the world's leading companies including Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, Johnson & Johnson, Medtronic, Millennium, Pfizer, Schering Plough, Smith & Nephew and Takeda Pharmaceuticals. Steve has also represented medical research institutions such as Cleveland Clinic, The Massachusetts General Hospital and Rockefeller University in connection with the spin-off or commercialization of their promising technologies. Steve has represented a number of entrepreneurs and venture capitalists in the life sciences industry, and the companies they have created, including AgeneBio, Alzheon, Blossom Innovations, Eléme Medical, InfoBionic, Normoxys, Percardia, pHLIP, Inc., Point Therapeutics, Salient Surgical, Vapotherm and Verax Biomedical.

Brad Flint advises a broad range of public and private company clients on start-up and formation matters, corporate governance, debt and equity financing, mergers and acquisitions, technology licensing and transfer, collaboration arrangements, supply and distribution agreements, and other general corporate matters. Brad represents clients in a variety of industries including biotechnology, pharmaceutical, medical device, software, and technology. He also regularly represents venture capital and private equity investors in connection with portfolio company investments and acquisitions.<

MedTech Frontiers, Thursday Evening, Nov. 2, 2017

Topic: "The Intersection of Big Data (BD) and Interactive Virtual Reality (IVR): It's All About Intuition

Speaker: Ron Schilling, PhD, Executive Chairman, EchoPixel

Date: Thursday, November 2, 2017, 6:00 - 9:00 pm, presentation begins at 6:45 pm
Location: Triple Ring Technologies, 39655 Eureka Drive, Newark, CA
Cost:

The seminar is free, but registration is required for planning purposes

Register at

<https://events.r20.constantcontact.com/register/eventReg?oeidk=a07eeres8wh0823a3e0&oseq=&c=&ch=>

About the Seminar:

Big Data (BD) and Interactive Virtual Reality (IVR) are increasingly garnering the interest from multiple disciplines and commitment from leading experts in these communities. Our speaker, Dr. Ron Schilling, a true luminary, will focus on the synergy between BD and VR, and the resulting potential for significant gains in Patient Outcomes (PO), an important dynamic for medical imaging.

It's quite clear that IBM's BD efforts with Watson are coming to fruition [1], and it's worth noting that Virginia Rometty, CEO, IBM, characterizes Watson as a Cognitive based system that applies machine learning techniques to BD. Cognition is indeed a critical element in that it impacts Knowledge, which is dependent on both Cognition and Intuition. Knowledge, in turn, represents a fundamental factor in driving PO. In addition, the other critical element in the Knowledge equation, Intuition, has been shown to be driven by IVR [2]. Hence, the power of the BD/IVR intersection.

Consider IVR as the ability to view an object in open 3D space and directly interact with the object (e.g. removing a tumor electronically). Radiologists note that IVR provides a tool with which to communicate more effectively with surgeons. Surgeons note that IVR allows them to finally achieve Surgical Visualization, the ability to view anatomy in a manner that corresponds to their 3D world view - n. b. they never open up patients and see 2D views.

Essentially, IVR represents a new paradigm, or "language," with which different specialists discover an enhanced ability for communicating more effectively with each other.

Why might 2017 be the key year to realize the potential of the BD/IVR Intersection? Based on several years of clinical trials, significant improvement in the core areas of PO, Clinical Efficacy (CE) and Workflow (WF), have been demonstrated in a number of applications, due to IVR driven increases in Knowledge.

We might think of IVR as focused on "doing the right things" and BD as focused on "doing things right." A case in point would be a Protocol for optimizing both CE & WF for Virtual Colonoscopy. Based on the intuitive properties of IVR, a concept of dividing the colon into linear segments emerged, with each segment separately analyzed for polyps [3]. This breakthrough led to significant gains in both CE & WF.

BD has already been effectively applied to Virtual Colonoscopy [4]. BD could also be applied to the analysis of all users of the above protocol to establish best practices from data representing all user motions (head, interaction tool, etc.). In this manner, BD is a key to "doing things right. [5]"

Therefore, the intersection of BD and IVR provides a significant opportunity for achieving improvements in PO. We could think of this activity as Knowledge

Modeling. Today, leading organizations in healthcare are establishing Knowledge Modeling as the core of effective data management. What could be better than to apply these principles to increasing PO?

Speaker Bio

Dr. Ron Schilling, Executive Chairman, EchoPixel, is amidst the opportunity of his lifetime - that is, to bring a truly disruptive technology to the medical imaging marketplace. Providing a solution to the cognitive strain that has been plaguing radiologists is what EchoPixel is all about. Using a combination of stereo (depth perception) and virtual holography (look around and direct interaction) provides physicians with increased intuition, enabling them to significantly increase knowledge. He has had the honor of working with outstanding luminary sites (USF, Stanford, Cleveland Clinic, and others). Ron has 35 years of operating and general management experience in the medical device and technology industries, at Toshiba, Diasonics and General Electric. He was a director at Stentor at 2007 when it was sold to Philips. He also teaches business strategy at Stanford and serves on several corporate boards in the medical field. Dr. Schilling earned his B.Sc. EE from City College of New York, his M.Sc. from Princeton University, and a PhD from the from the Polytechnic Institute of New York University.

- [1] WSJ. 2016 Oct; P12, Rometty, V, (IBM).
- [2] Schilling RB. Bridging the Radiology - Surgery Gap. SPIE/IFCARS. Workshop on Information Management, for the Digital Operating Room. 2016 Feb 27.
- [3] A Game Changer in CT Colonography. J. Yee DI Europe, Vol 32, #6.
- [4] Gastroenterology. 2005 Dec;129(6):1832-44.
Computed tomographic virtual colonoscopy computer-aided polyp detection in a screening population.
Summers RM, Yao J, Pickhardt PJ, Franaszek M, Bitter I, Brickman D, Krishna V, Choi JR.
- [5] Shrestha RB. Connecting big data to big insights. App Radiol. 2016;3;38.

Bio2Device Group, Tuesday Morning, Nov. 7

Speaker: Atta Pilram, President, President, Care Anytime
Date and Time: Tuesday morning, Nov. 7, 2017, - 8:30am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
There is no fee or registration required for morning meetings.

Speaker Bio

Atta Pilram, President – Prior to starting Care Anytime, he started TebiaMED in 2013 as a non-profit company with a unique care adherence management tool for patients with diabetes. In 2014, he cofounded CLOVI Corporation (CLOVI.net) as a SaaS based health informatics platform for managing health and wellness information in the corporate segment. He grew the company from idea stage to its revenue phase before his departure at the end of 2016 to start Care Anytime. From 2008 to 2010, he was an active mentor at UCSF Idea to IPO program, advising a community of physicians, medical professionals and post-docs to guide them in formulating their Bio-med products and service ideas into sound business strategies. In 1994, he founded Affinity Network Services, a pioneering company offering Telemedicine integration services that merged with World Internet Center.

Rosenman Institute Partnering Day, Wednesday, November 8, 2017

Event: Meet one-on-one with Nipro Corp., a leading Japanese medtech company
Date: Wednesday, November 8
Location: UCSF Mission Bay
Deadline to apply is 11:59 pm, Wednesday, Nov. 1
Apply at http://www.surveygizmo.com/s3/3891075/Meet-with-Nipro-at-UCSF-Mission-Bay-November-2017?mc_cid=7cec087446&mc_eid=cb4c38a44a

Event Description

Nipro Corporation is a global medical device company headquartered in Japan whose worldwide sales in 2016 exceeded \$3 billion. Nipro, a partner of the Rosenman Institute, is looking to develop and acquire innovative technologies that complement and strengthen its IP portfolio. They're interested in meeting startups in our ecosystem.

The Rosenman Institute is coordinating a partnering session on Wednesday, November 8 at UCSF Mission Bay. Space is limited. If you see an opportunity in partnering with Nipro, please apply online. The deadline is midnight on November 1.

Rosenman, Tuesday, Nov. 9, 2017

Event: "Rosenman D-Series: A Conversation with Matt Likens"
Speaker: Matthew Likens, President and CEO of GT Medical Technologies
Date and Time: Thursday, Nov. 9, 2017, 5:00 PM – 6:30 PM PST
5:00 - 5:30 pm: Networking
5:30 - 6:30 pm: Talk and Q&A
Location: Room 212, Byers Hall, 1700 4th Street, UCSF Mission Bay, San Francisco, CA 94158
Fee: \$10 general admission
Details and registration at https://www.eventbrite.com/e/rosenman-d-series-a-conversation-with-matt-likens-tickets-38979097530?mc_cid=570318eeb9&mc_eid=cb4c38a44a

Event Description

Join us on Thursday, November 9, when Rosenman Institute Director Christine Winoto will interview Matthew Likens, a serial startup CEO with a track record of impressive success. How do you lead a startup from its founding to IPO or acquisition? How do you keep investors on your side through the hard times? We look forward to seeing you at the next D-Series.

Speaker Bio

Matthew Likens is currently President and CEO of GT Medical Technologies, the makers of GammaTiles, with the goal of improving the lives of brain tumor patients. After graduating cum laude from Kent State University, Mr. Likens began his professional career with Johnson & Johnson Corporation. He then spent more than twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the position of President, Baxter Biotech North America, followed by President of Baxter’s Renal Division in the U.S. In July of 2006, Mr. Likens became President and CEO and the second employee of Ulthera, Inc., a venture capital-backed start-up company in energy-based aesthetics in Phoenix, AZ. After filing for an initial public offering in early 2014, Ulthera was

acquired by Merz Pharma GmbH for \$600M, an amount representing 6.6x trailing 12-months' revenue. The Arizona Association for Corporate Growth (ACG) recognized this as Transaction of the Year for 2014.

Phoenix Business Journal honored Mr. Likens in 2012, naming him one of Arizona's Most Admired CEOs.

In June of 2015, Ernst & Young presented Mr. Likens with the Entrepreneur of the Year for the Mountain Desert Region Award.

Mr. Likens is a member of the board of directors of Luma Therapeutics, an early-stage company with a promising treatment for psoriasis, and an adviser to Genteract, an early-stage genetics company. He is a member of the Greater Phoenix Economic Council Healthcare Innovation committee and a member of the City of Mesa Economic Development Council.

Bio2Device Group, Tuesday Evening, Nov. 14, 2017

Topic: "Sprout Medical, Making an Impact in Critical Care"

Date and Time: Tuesday, Nov. 14, 2017, 6:00 pm

Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto

Jerry Gibson, Chairman & CEO, Sprout Medical

Cost:

\$6 - Students/In-transition - Members only

\$11 - Early-bird Registration - Members only

\$20 - Late Registration and Non-Members

\$25 - Walk-ins

Register on website at www.Bio2Devicegroup.org

Topic Description

Sprout Medical has developed a cost-effective system to increase the clinical efficiency of administering the rapid infusion of various fluids that are so important in the treatment of sepsis, trauma and other critical conditions in the ED, ICU, OR and pre-hospital environments. Mr. Gibson will review the clinical and competitive landscape as well as Sprout Medical's approach to tackling this important issue.

Speaker Bio

Mr. Gibson has over 35 years of executive experience in the medical device field in the capacity of Division Manager at Siemens Medical Solutions and in the positions of CEO, founding President and Senior V.P. of Sales & Marketing of several medical startups and technology turnaround companies. In addition, Mr. Gibson presently serves on several Boards of medical technology startup companies in addition to having served as a member of the External Advisory Board of the University of California/National Science Foundation Center for Biophotonics Science and Technology. Mr. Gibson earned a Bachelor of Business Administration degree from the University of Memphis.

EMBS, Wednesday Evening, Nov. 15, 2017

EMBS Chapter meeting on Wednesday, November 15, 2017, which will include an invited speaker.

Speaker: Steve Axelrod, CEO of G-Tech Medical

Follow for details at <http://www.ewh.ieee.org/r6/scv/embs>

Topic Description

Early results from proof of concept clinical trials with G-Tech Medical's "EKG for the Gut"

Brief summary: Motility, the movement through the digestive tract of what starts out as food, is usually taken for granted, until something goes wrong. There are a wide range of gastrointestinal (GI) disorders and dysfunctions that can be blamed on motility issues. G-Tech has developed electrode patches worn on the abdomen that read electrical signals emanating from the muscles of the stomach, small intestine and colon when they are active – driving motility – that are thin, wireless and non-invasive. Over the past two years G-Tech has launched clinical trials with patients recovering from abdominal surgery and with patients with Parkinson’s disease. Interesting results have been obtained in these cases and also in volunteer tests, and will be described in the talk.

More details will be provided in our EMBS-SCV November announcement

WIB -National Webinar, Wednesday, Nov. 15, 2017

Topic: "Project Management – How Good Leadership Can Make or Break Project Success"

Date and Time: November 15, 2017, 1:00 p.m. – 2:00 p.m. EST*

Registration Deadline: November 14, 2017

Venue: Registrants will receive a webinar link via confirmation email

Webinar Description

A project manager’s role goes beyond the management of scope, budget, and schedule. Members of a project team are human beings with human feelings, and a successful project manager must also encourage, motivate, and relate to the members on his or her team. A challenge in project management is how to assure that things get done while motivating the team to deliver. During this webinar Gretchen Stup, Senior Consultant, Latham BioPharm Group, will focus on leadership styles that are effective, influential, and valuable, so as to contribute to the success of your project.

This course will result in up to one hour of PMI-approvable Professional Development Units (PDUs) for the project management field

QB3, Thursday Midday, Nov. 17, 2017

Event: Seminar for Entrepreneurs, "Destroyer of Obstacles': Going..."

Speaker: Eric Hobbs, CEO, Berkeley Lights

Date and Time: Thursday, Nov. 17, 2017, 12:00 to 1:00 pm

Location: Room N-114, Genentech Hall, 600 16th Street, UCSF Mission Bay, San Francisco, CA 94158

Fee: \$10 general admission

Details and registration at https://www.eventbrite.com/e/qb3-seminar-eric-hobbs-berkeley-lights-destroyer-of-obstacles-going-from-startup-to-a-commercial-tickets-38824104943?mc_cid=570318eeb9&mc_eid=cb4c38a44a#tickets

Speaker Bio

Eric Hobbs leads Berkeley Lights, an East Bay company developing nanofluidic technology that enables cell selection for drug discovery, cell line development, and

cell therapy manufacturing. The SF Business Times recently profiled Hobbs as a "destroyer of obstacles." Under his leadership, Berkeley Lights has hit revenue and budget targets, despite having lost 40 staff just before Hobbs took the helm. How does he face and overcome such challenges, and what has his professional journey been like? Join us November 16 to hear for yourself.

About the Speaker

Eric Hobbs

Eric D. Hobbs joined Berkeley Lights in May 2013 and was appointed Chief Executive Officer in March 2017. Prior to becoming CEO, Eric held various senior management roles, including most recently, Senior Vice President of Operations and Consumables. Prior to Berkeley Lights, Eric led the design, development, and launch of 3 new product architectures at FormFactor, Inc. as a senior member of both R&D and Operations organizations. He holds more than 62 U.S. and International patents. Eric has lectured both at UC Berkeley and Stanford speaking on Engineering Design, Invention, and Optimization Algorithms. Eric earned his Ph.D. & M.S. in MEMS Design and Microfluidic Devices at UC Berkeley. He received a B.S. in Mechanical Engineering from U.S.C.

PBSS Workshop, Monday, Dec. 11, 2017

Event Name: Clinical Pharmacology & Modeling Strategies for your Drug Development Program: Fundamentals, Best Practices and Real World Applications

Speakers: David Lau (Foresee Pharmaceuticals), Geoff Banks (Nuventra), Mark Sale (Nuventra), Lauren Lohmer (Nuventra)

Date and Time: Monday, Dec. 11, 2017, 8:45-17:00

Preliminary Agenda

8:45 – 9:00 Welcome and Intro

9:00 – 10:30 – David Lau (Senior Vice President, NCE Preclinical and Clinical Development, Foresee Pharmaceuticals)

Purpose of Clin Pharm Studies in Drug Development

Type of Clin Pharm studies (SAD, MAD, BA/BE, DDI, Disease population, QT, etc)

- What are these studies
- When to do the studies
- Typical study design
- Examples

10:30 – 11:00 – Break and Vendor Presentation

11:00 – 12:30 – Geoff Banks (CEO, Nuventra)

How to Form a Clin Pharm Strategy for your NDA / BLA

- What studies you do & don't need
- "Gap analysis" in your program
- Real world examples

12:30 – 1:30 – Lunch

1:30 – 3:00 – Mark Sale (Senior Vice President, Pharmacometrics, Nuventra)

Modeling & Simulation / Population PK Fundamentals

- What is it?
- How do you do it?
- Allometric scaling
- How do you use it for safety and efficacy?

3:00 – 3:30 Break and vendor presentation

3:30 – 5:00 – Mark Sale and Lauren Lohmer (Manager, Clinical Pharmacology, Nuventra)

Using Modeling & Simulation to Avoid Clinical Trials

- Overview and case studies:
 - CQT

- Exposure response
- Additional DDI studies
- Special population studies
- Renal impairment

Location: SF Bay Area: Foster City Crowne Plaza

Registration fee (US\$): Academic: \$125; Regular: \$195; For unemployed or students: \$30; For major-sponsor rep (incl lunch): \$0; For vendor-show rep: \$35;

Details and registration at <http://www.pbss.org/asp/eventInfo.aspx?eID=557>

Registration deadline: 12/8/2017 (it will close sooner if the seating cap is reached)

This is a friendly reminder that you have not registered for the following Workshop . If you plan to attend, please register at www.pbss.org before it is closed (it may close BEFORE the deadline if the seating capacity is reached early).

JLABS, Thursday Morning, Jan. 25, 2017

Topic: "Who's Who in 2018: A Strong Finish to 2017 Healthcare Investing?"

Speaker: Jonathan Norris | Managing Director, Silicon Valley Bank

Date and Time: Thursday, January 25, 2018 from 8:00 AM to 10:00 AM (PST)

Agenda:

8:00 AM | Registration, Breakfast & Networking

8:30 AM | Presentation - Q&A

9:30 AM | Networking

10:00 AM | Program Close

Location:

JLABS @ SSF

329 Oyster Point Blvd - 3rd Floor

South San Francisco, CA

Fees:

\$12 | General Public

\$8 | Student/Academic

\$25 | At the door

Details and registration at <https://www.eventbrite.com/e/whos-who-in-2018-a-strong-finish-to-2017-healthcare-investing-tickets-36706212269?aff=weekly>

Event Details

2017 saw a banner first half, driven in part by advancements in artificial intelligence and machine learning for healthcare applications and a surge in Series A investments. With 2017 in the review mirror, Jon Norris takes a look at – and makes sense of – the past trends to provide an informed look into 2018.

As the 2018 investment market takes shape, what can we expect for the IPO and M&A markets? Jon will share his expertise and provide insight into:

How the 2017 healthcare landscape compares to previous years

Current and total healthcare and sector investments

Which Biopharma indications attracted the most funds

Which venture firms are most active

Changes in the past crossover phenomenon

Exits: the trends in IPOs and M&A's

At the end of this talk you should be informed as to who is investing, and the type of deals and exits that are likely to be executed in 2018.

Presenter's Biography:

Jonathan Norris | Managing Director, Silicon Valley Bank

Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations.

In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms.

Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

About Jon Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.

JLABS, Thursday Morning, Feb. 2, 2018

Event: "Meet With...Versant Ventures"

Speakers: Graham G. Walmsley | Investment Professional, Versant Ventures and Lev Osherovich | Director of Innovation Sourcing, Versant Ventures

Date and Time: Thursday, February 1, 2018 from 10:30 AM to 1:00 PM (PST)

Agenda:

10:30AM | Registration and Networking

11:00 AM | Presentation and Q&A

12:00 PM | Networking Lunch

1:00-5:15 PM | One-on-One Meeting* (30 - minute meetings)

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due January 4, 2018. Apply Here.

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd, 3rd Floor South San Francisco, CA

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Details and registration at <https://www.eventbrite.com/e/meet-with-versant-ventures-tickets-36705327623?aff=weekly>

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with Graham Walmsley of Versant Ventures. Your application will be reviewed and you will be notified of acceptance on Wednesday, January 18th, 2018. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details

Committed to transforming the healthcare landscape through innovation, Versant Ventures is eager to help you make an impact in healthcare. Graham Walmsley, MD,

Ph.D. and Lev Osherovich, Ph.D. of Versant Ventures will be visiting JLABS @ SSF on February 1, 2018 to provide an overview of Versant's unique investment strategies and meet 1-on-1 with pre-selected companies.

*The one-on-one application process is separate from the event registration process. Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by January 4th. [Apply Here](#).

Program Overview:

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs who are building the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With \$2.3 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, nearly 70 Versant companies have achieved successful acquisitions or IPOs.

Graham Walmsley, MD, Ph.D. and Lev Osherovich, Ph.D. will be in attendance to provide an overview presentation of their firm's area of interest. They will be on hand to meet with a handful of applicants 1-on-1 after the presentation. To be considered for a 1-on-1 meeting complete the information required here. Applications due by January 4, 2018.

Speakers' Biographies:

Graham G. Walmsley | Investment Professional, Versant Ventures

Graham G. Walmsley, M.D., Ph.D. is an Investment Professional at Versant Ventures focused on biotechnology and healthcare investments. Graham joined Versant after completing his training as a Physician Scientist Fellow at Stanford University School of Medicine. At Versant, Graham helped build and launch BlueRock Therapeutics, a regenerative medicine company formed in collaboration with Bayer through one of the largest series A investments (\$225M) in biotech history.

Graham received his M.D. and Ph.D. in Stem Cell Biology and Regenerative Medicine from Stanford University and earned his B.A. in Molecular and Cell Biology with summa cum laude honors from the University of California, Berkeley. He conducted his thesis work in the laboratories of Irving Weissman and Michael Longaker with a focus on regenerative medicine, stem cells, and therapeutic approaches to fibrosis. This work was featured in TIME Magazine and resulted in several patents as well as over 60 peer-reviewed publications in journals such as Science and Cell.

Lev Osherovich | Director of Innovation Sourcing, Versant Ventures

Lev Osherovich, Ph.D. is Director of Innovation Sourcing at Versant Ventures, where he focuses on early stage therapeutic investment. Lev trained in Molecular and Cell Biology at UC Berkeley (undergraduate) and in Biochemistry at UCSF, and completed postdoctoral training at University of Kent at Canterbury and UCSF. After leaving academia, he worked as a biotech industry analyst and science journalist at

BioCentury and Nature Publishing Group. Since 2014, Lev has worked at Versant and its discovery engine, Inception Sciences, to evaluate academic research with translational potential and to create new portfolio companies.

JLABS, Tuesday Morning, Feb. 6, 2018

Topic: "The Art and Science of Productive FDA Meetings"

Speaker: Ron Farkas, MD PhD, Vice President, Technical, PAREXEL Consulting

Tuesday, February 6, 2018 from 10:30 AM to 1:00 PM (PST)

Agenda:

10:30 AM | Registration & Networking

11:00 AM | Presentation

11:40 AM | Q&A

12:00 PM | Networking Lunch

1:00 PM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, CA

Fees:

\$25 | General Public

\$10 | Student/Academic

\$35 | At the door

Details and registration at <https://www.eventbrite.com/e/the-art-and-science-of-productive-fda-meetings-tickets-37017978771?aff=weekly>

Event Details

Getting solutions to patients can be a long and complicated process. Working with the FDA is a key part of the sequence. Preparing for and understanding the FDA's needs is essential to smooth the way and shorten your time to approval.

Johnson & Johnson Innovation, JLABS is happy to be hosting Ron Farkas, MD PhD, Vice President, Technical, PAREXEL Consulting, to discuss the ins and outs of FDA meetings. Ron will pull from his vast experience which includes a decade plus run at the FDA to help guide us through these vital interactions. Topics will include:

Understanding the FDA's position; not just what it wants but why

What to agree on now and later; What does agreement mean?

The key to proceed

Understanding the dynamics within the FDA

Flexibility and norms and what they mean

Experts, Patients and Advocates at Meetings

Meeting minutes and follow up

Understanding the process will help you better prepare for your meetings and build confidence in and ability to adjust your own plan. Come prepared with your questions!

Speaker Bio

Ron Farkas | Vice President, Technical, PAREXEL Consulting

Dr. Ronald Farkas is a senior regulatory professional with over 15 years of experience in all phases of drug development from preclinical development through marketing application, advisory committee meetings, labeling negotiations, and the post-approval period. Dr. Farkas has in-depth cross-disciplinary expertise in clinical safety and efficacy, clinical pharmacology and pharmacogenomics, preclinical development, statistical analysis, and biomarker/surrogate endpoint development and utilization.

Dr. Farkas uses his extensive scientific, drug development and regulatory experience to assist clients in negotiating with regulatory authorities across the entire product life cycle to achieve their company objectives.

Prior to joining PAREXEL, Dr. Farkas was a Cross-Disciplinary Team Leader at FDA in CDER's Division of Neurology Products, with prior assignments to the Office of New Drugs Guidance and Policy Team and the CDRH Office of Device Evaluation. Prior to joining the FDA, Dr. Farkas was an assistant professor and attending surgeon at the Johns Hopkins University Wilmer Ophthalmic Institute.

Dr. Farkas completed residency training in ophthalmology at the Harvard University School of Medicine Massachusetts Eye and Ear Infirmary, subsequent to earning dual MD and PhD degrees in neuroanatomy and neuropharmacology from the University of Illinois at Chicago School of Medicine.

JLABS, Thursday Mid Day, March 29, 2018

Event: Meet With... Frazier Healthcare Partners

Speakers: James W. Brush, M.D. | Senior Associate, Frazier Healthcare Partners and Patrick Heron, MBA | Managing General Partner, Frazier Healthcare Partners

Date and Time: Thursday, March 29, 2018 from 10:30 AM to 1:00 PM (PDT)

Agenda:

10:30AM | Registration and Networking

11:00 AM | Presentation and Q&A

12:00 PM | Networking Lunch

1:00-5:15 PM | One-on-One Meeting* (30 - minute meetings)

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 22,, 2018. Apply Here.

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with Jamie Brush of Frazier Healthcare Partners. Your application will be reviewed and you will be notified of acceptance on March 13th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Details and registration at <https://www.eventbrite.com/e/meet-with-frazier-healthcare-partners-tickets-36705859213?aff=weekly>

Event Description

With over 26 years of exclusively investing in over 170 healthcare companies, Frazier Healthcare Partners has a great deal of experience building successful life science businesses. On March 29, 2018, Jamie Brush MD, and Patrick Heron, MBA will be visiting JLABS @ SSF to provide an overview of Frazier Healthcare Partners' unique investment strategies and meet 1-on-1 with pre-selected companies.

*The one-on-one application process is separate from the event registration process. Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by February 22nd. [Apply Here](#).

Program Overview:

Frazier Healthcare Partners is committed to helping great healthcare companies who are working hard to make a difference in the future of life sciences. The firm has partnered with exceptional entrepreneurs at all stages and focuses on therapeutic development. With \$3 billion under management, investments in over 170 companies and 35 IPOs, Frazier Healthcare Partners has built a team with deep knowledge and scientific expertise that enables company building.

Jamie Brush, MD and Patrick Heron, MBA will be in attendance to provide an overview presentation of the firm's areas of interest. They will be on hand to meet with a handful of applicants 1-on-1 after the presentation. To be considered for a 1-on-1 meeting, please complete the information required [here](#). Applications due by Feb 22, 2018.

Speakers' Biographies:

James W. Brush, M.D. | Senior Associate, Frazier Healthcare Partners

Jamie joined Frazier Healthcare Partners in 2016 and focuses on investment identification, due diligence, and deal closing.

Before joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing and business development strategy.

Jamie received his M.D. from the University of Southern California, where he was inducted into Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his postgraduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston. He has co-authored several papers in top-tier journals on genomic instability and its role in cancer, and is a member of the board of directors of Longwood Symphony Orchestra.

Patrick Heron, MBA | Managing General Partner, Frazier Healthcare Partners

Patrick is a Managing General Partner of Frazier's Life Sciences team. He joined the firm in 1999 and opened Frazier's Menlo Park office in 2003. Throughout his 12 years as General Partner, Patrick has led or co-led investments across nearly 20 companies.

Patrick has successfully partnered with entrepreneurs across a range of company types and stages, from early – stage anti-infectives companies to >\$100M commercial-stage dermatology companies. Patrick has also been active in company formation around both early – and later – stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including Tobira Therapeutics (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL). He currently serves on the boards of Imago BioSciences, Iterum Therapeutics, Silvergate Pharmaceuticals, SutroVax and Zavante Therapeutics.

Prior to joining Frazier, Patrick helped develop McKinsey & Company's West Coast biotechnology consulting practices, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.

Patrick received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.